New Day DiagnosticsEARLY DETECTION SIMPLIFIED
We strive to make early detection of cancer
not only possible, but also simple.
Point-of-Care (PoC) Diagnostics
Beyond improving test performance, we strive to create tests that are simple and accessible to promote more regular testing of diseases. We’ve based our ovarian and prostate cancer tests on novel biomarkers present in urine.
Early and accurate detection is essential for success in treatment of ovarian cancer. Unfortunately the majority of existing tests lack the ability to accurately detect the cancer in its early stages. We are utilizing a novel biomarker to develop a test that will demonstrate higher specificity and sensitivity for ovarian cancer compared to existing methods of detection.
ProCare Diagnostics is utilizing a new urinary biomarker, which has the potential to be more accurate than other common prostate cancer markers in detecting and monitoring prostate cancer, as well as guiding therapy.